83
Participants
Start Date
February 29, 2008
Primary Completion Date
April 30, 2009
Study Completion Date
January 31, 2011
Sorafenib (Nexavar, BAY43-9006)
The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
Marseille
Milan
Pavia
Hanover
Bordeaux
Aviano
Marburg
Tours
Nantes
Mainz
Tübingen
Paris
La Roche-sur-Yon
Jena
Olsztyn
Warsaw
Warsaw
Wroclaw
London
Greater Manchester
Cardiff
Glasgow
Lead Sponsor
Bayer
INDUSTRY